Medicament for treating osteoporosis

A technology for osteoporosis, medicine, applied in the field of pharmaceutical preparations

Inactive Publication Date: 2013-08-14
CP PHARMA QINGDAO CO LTD
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] In order to solve the problem of osteoporosis prone to occur in women after menopause, the present invention provides a comprehensive, safe and effective drug combination for preventing and treating postmenopausal osteoporosis in women, which uses alfacalcidol and alendronate sodium in combination For the treatment of osteoporosis, it can make up for the shortcomings of alendronate sodium when it is used alone, and give full play to the efficacy of the two drugs, which can achieve a good therapeutic purpose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] This embodiment is the preparation of alfacalcidol and alendronate sodium tablet:

[0020] Alfacalcidol 0.1g

[0021] Alendronate Sodium 2000g

[0022] Microcrystalline Cellulose 1000g

[0023] Starch 200g

[0024] Sodium Carboxymethyl Cellulose 100g

[0025] Magnesium Stearate 20g

[0026] 3% polyvinylpyrrolidone ethanol solution appropriate amount

[0027] 200000 pieces

[0028] Preparation Process:

[0029] Mix alfacalcidol sodium alendronate, microcrystalline cellulose, starch, and sodium carboxymethylcellulose evenly, add 3% polyvinylpyrrolidone ethanol solution to make a soft material, granulate with a 14-mesh sieve, and place After drying at 70-80°C, sieve through a 12-mesh sieve, add magnesium stearate, mix well, and press into tablets.

Embodiment 2

[0031] This embodiment is the preparation of alfacalcidol and alendronate sodium granules:

[0032] Alfacalcidol 0.1g

[0033] Alendronate Sodium 2000g

[0034] Corn starch 2000g

[0035] Mannitol 2000g

[0036] Sucrose 8000g

[0037] Sodium Carboxymethyl Cellulose 1000g

[0038] 10% starch slurry appropriate amount

[0039] 200000 bags

[0040] Preparation Process:

[0041] Pass alfacalcidol, alendronate sodium, mannitol, corn starch, sucrose, and sodium carboxymethylcellulose through a 100-mesh sieve, weigh according to the prescription, mix well, and add 10% starch slurry to make a soft The materials are granulated with a 14 mesh sieve, dried at 70-80°C, granulated with a 12 mesh sieve, and packed separately.

Embodiment 3

[0043] This embodiment is the preparation of Alfacalcidol and Alendronate Sodium Dropping Pills:

[0044] Alfacalcidol 0.1g

[0045] Alendronate Sodium 2000g

[0046] Polyethylene glycol 6000 18000g

[0047] 200000 capsules

[0048] Preparation Process:

[0049]Take polyethylene glycol 6000 and heat it to melt, add alfacalcidol and alendronate sodium, stir continuously to make it all melt, filter it into the liquid storage tank while it is hot, keep it warm, use a dropper at a rate of 90 drops / min Dropping, drop into the liquid paraffin cooling liquid containing 43% kerosene, cool to form pills, and then wash the pills with liquid paraffin until there is no kerosene smell.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicament for treating postmenopausal osteoporosis of women. The medicament is characterized by containing alfacalcidol and alendronate sodium. The alfacalcidol and the alendronate sodium have the same point and the different points on the mechanism of action. By utilizing the alfacalcidol and the alendronate sodium, complementation of the mechanism of action can be realized, the defect of single mechanism is remedied, and treatment to face osteoporosis is better realized.

Description

technical field [0001] The invention relates to a pharmaceutical preparation, in particular to a compound preparation of alfacalcidol and alendronate sodium, belonging to the technical field of medicine. Background technique [0002] Osteoporosis is a common senile disease. According to statistics, there were about 84 million osteoporosis patients in my country in 1999, and 120 million people in 2010. It is estimated that by 2050, the number of osteoporosis patients will reach 212 million. At present, it has been called a "silent epidemic" by the World Health Organization (WHO), and it ranks seventh among the world's common and frequently-occurring diseases, and the number of patients has exceeded 250 million. According to another survey, the incidence rate of osteoporosis in my country is 21% for those aged 50-60, 58% for those aged 60-70, and nearly 100% for those over 70 years old. Postmenopausal women in particular have a higher incidence of osteoporosis and fracture co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/663A61P19/10A61K31/593
Inventor 王明刚任莉陈阳生臧云龙汪泓牛建兴
Owner CP PHARMA QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap